Expert Opinion on Pharmacotherapy

Long-term, open-label evaluation of the safety and efficacy of telmisartan 80 mg/hydrochlorothiazide 25 mg fixed-dose combination alone or with other antihypertensive medication
pp. 345-352(8)
Authors: Neldam, Steen; Edwards, Colin

Pharmacotherapy of patients with schizophrenia and substance abuse
pp. 353-367(15)
Authors: Wobrock, Thomas; Soyka, Michael

Pharmacotherapy of acute coronary syndrome: the ACUITY trial
pp. 369-380(12)
Authors: Mukherjee, Debabrata; Eagle, Kim A

Tuberculosis pharmacotherapy: strategies to optimize patient care
pp. 381-401(21)
Authors: Mitnick, Carole D; McGee, Bryan; Peloquin, Charles A

Treatment options for AIDS patients with progressive multifocal leukoencephalopathy
pp. 403-416(14)
Authors: Hernández, Beatriz; Dronda, Fernando; Moreno, Santiago

A review of current anti-HCV treatment regimens and possible future strategies
pp. 417-433(17)
Authors: Neukam, Karin; Macías, Juan; Mira, José A; Pineda, Juan A

Pharmacotherapy of helminth infection
pp. 435-451(17)
Author: van den Enden, Erwin

Pathophysiologic basis for the medical management of portal hypertension
pp. 453-467(15)
Authors: Poordad, Fred F; Sigal, Samuel H; Brown, Robert S

Pharmacotherapy of gastroparesis
pp. 469-484(16)
Authors: Reddymasu, Savio C; McCallum, Richard W

Clinical benefits versus shortcomings of diltiazem once-daily in the chronotherapy of cardiovascular diseases
pp. 485-491(7)
Authors: Ezeugo, Ugochukwu; Glasser, Stephen P

Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)
pp. 493-501(9)
Authors: Mitsogiannis, Iraklis C; Skolarikos, Andreas; Deliveliotis, Charalambos

Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
pp. 503-512(10)
Author: Pratley, Richard E

New findings with old drugs for osteoporosis
pp. 513-516(4)
Author: Doggrell, Sheila A